Guardian Pharmacy Services, Inc.
NYSE:GRDNMedical - Distribution
+$0.17 today
- Market cap
- $3.09B
- Beta
- 0.08
- P/E (TTM)
- 52.0
- EPS (TTM)
- $0.84
Volume 0.45M
Average 0.48M
GRDN Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Guardian Pharmacy Services, Inc.NYSE: GRDN
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables turns negative
Q2 FY2026 accounts payables was -$248K, compared with $1.88M a year earlier. Trailing-twelve-month accounts payables was $4.6M. Over 3 fiscal years it compounded at +7.1% a year.
Context
- Accounts payables amounted to 1.1% of revenue in FY2025, unchanged from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$248K or moves back toward the trailing-twelve-month quarterly average of $1.15M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 16.4M USD
- Year-over-year change
- +23.9%
- 4-year CAGR
- +13.8%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.4M | +23.9% |
| FY2024 | 2024-12-31 | 13.23M | +110.2% |
| FY2023 | 2023-12-31 | 6.3M | -52.9% |
| FY2022 | 2022-12-31 | 13.37M | +36.7% |
| FY2021 | 2021-12-31 | 9.78M | — |
Accounts Payables vs competitors
How GRDN compares with its peers on the latest reported figures
- GRDN's LTM Jun 2026 accounts payables of $4.6M is the 6th largest of the 11 companies compared; the peer median is $1.73M.
- Its year-over-year change of -18.5% is the 8th highest of 10, against a peer median of +144.1%.
- Accounts payables amounts to 0.3% of revenue for GRDN, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $74.44M | -260.2% | +307.1% | 3.8% | |
| LTM Jun 2026 | $16.07M | -193.4% | — | 9.5% | |
| LTM Sep 2026 | $13.93M | +49.2% | — | 3.0% | |
| LTM Mar 2026 | $13.6M | +197.1% | +19.4% | 0.5% | |
| LTM Sep 2026 | $8.53M | +1178.4% | +79.5% | — | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $4.6M | -18.5% | +7.1% | 0.3% |
| LTM Mar 2026 | $4.43M | +13.2% | +18.9% | 1.4% | |
| LTM Jun 2026 | $2.46M | +144.1% | — | 0.4% | |
| LTM Sep 2026 | $1.86M | +1087.3% | -21.0% | 0.1% | |
| LTM Mar 2026 | $1M | +148.6% | — | 4.6% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GRDN) | $1.73M | +144.1% | +19.4% | 1.4% | |
Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 28.33M | 49.66M | 37.72M | (71.03M) | 49.22M |
| Depreciation & Amortization | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3.07M |
| Stock-Based Compensation | 13.03M | (3.38M) | (6.09M) | 131.49M | 13.85M |
| Change in Working Capital | (1.47M) | (18.72M) | 15.6M | (29.41M) | 6.38M |
| Accounts Receivables | (7.71M) | (16.79M) | (14.3M) | (25.49M) | (8.55M) |
| Inventory | (240K) | (8.12M) | 4.43M | (1.15M) | (877K) |
| Accounts Payables | 9.78M | 13.37M | 6.3M | 13.23M | 16.4M |
| Other Working Capital | (3.3M) | (7.17M) | 19.18M | (16M) | (586K) |
| Other Non-Cash Items | 2.08M | 4.4M | 5.35M | 7.14M | 5.43M |
| Operating Cash Flow | 58.5M | 48.52M | 70.82M | 57.96M | 100.29M |
| Capital Expenditures | (9.28M) | (16.77M) | (14.56M) | (16.37M) | (19.58M) |
| Acquisitions (Net) | (4.4M) | (2M) | (985K) | (14.71M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 535K | 874K | 2.1M | 671K | (12.68M) |
| Investing Cash Flow | (13.15M) | (17.9M) | (13.44M) | (30.41M) | (32.26M) |
| Debt Repayment | (6.1M) | (2.8M) | (2.89M) | (36.48M) | (4.98M) |
| Common Stock Issued | 0 | 0 | 0 | 119.78M | 27.45M |
| Common Stock Repurchased | 0 | 0 | 0 | (55.18M) | (29.04M) |
| Dividends Paid | (17.36M) | (30.8M) | (38.42M) | (35.75M) | 0 |
| Other Financing Activities | (13.34M) | (11.42M) | (15.92M) | (16.02M) | (497K) |
| Financing Cash Flow | (36.79M) | (45.03M) | (57.23M) | (23.65M) | (7.07M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.56M | (14.41M) | 145K | 3.91M | 60.96M |
| Free Cash Flow | 49.22M | 31.75M | 56.26M | 41.59M | 80.71M |
Guardian Pharmacy Services, Inc.
NYSE:GRDN
Intrinsic Alpha fair value
Locked
Current Price
$48.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.